ADDRESS: Street, City, Country
PHONE: +(123) 456 789
E-MAIL: your-email@mail.com
The future of obesity care will involve multidisciplinary collaboration between physicians, dieticians, fitness professionals and patient support teams, says Ajanta Pharma.
imphoenix82
Last month, Ascletis received US FDA IND clearance to initiate a Phase I clinical trial evaluating its once-monthly Self-Assembling Lipid Depot (SALD) formulation of ASC35 as a subcutaneous treatment for obesity.
imphoenix82
Lilly sees retatrutide as part of a broader portfolio approach to obesity care alongside its existing therapies Zepbound (tirzepatide) and Foundayo (orforglipron).
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 8447496924
HealthXploreIndia @2026. All Rights Reserved.
